Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

A lot of promise but a long way to go: an initial assessment of the EU adaptive pathways pilot

This article was originally published in SRA

Executive Summary

With its emphasis on involving a range of key stakeholders in discussions at a very early stage in the drug development process, the adaptive pathways approach to drug evaluation and market access being spearheaded by the European Medicines Agency is "unique worldwide at the moment". However, "this particular pilot has been under-resourced at all levels" and it will take "three to five years" to see whether it does in fact meet its objective of cutting drug development times and getting products to patients faster.


Related Content

Adaptive Pathways: Companies Advised To Consider Hurdles As EMA Accepts More Applications



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst